Zac

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zac

This foundational section defines Zac by its chemical structure, classification, and general function, strictly adhering to principles of absolute factual accuracy and expertise.

Property Description
Active ingredient Fluoxetine (most often as Fluoxetine Hydrochloride)
Form Oral Solid Forms (Capsules, Tablets), Oral Solution
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
General purpose Neurochemical balance and mood stabilization
Origin Synthetic Compound

What Type of Medicine is Zac and What is its Purpose?

Zac is a prescription-only medication whose active substance is Fluoxetine (Fluoxetine Hydrochloride), which functions as a Selective Serotonin Reuptake Inhibitor (SSRI), a specialized type of Antidepressant and Psychotropic agent. The specific purpose of this drug is to manage and modulate chemical signaling within the central nervous system. Fluoxetine is highly recognizable in the medical community.

The mechanism of action centers on targeting a natural chemical messenger, serotonin, by inhibiting its reabsorption (reuptake) by nerve cells. By sustaining higher functional levels of serotonin in the spaces between nerve cells, the medicine is designed to facilitate a gradual stabilization of emotional state and support overall mood regulation. As a psychotropic agent, it is designed to modify serotonin levels to improve persistent emotional dysregulation. This indicates the medicine's general role is to help restore emotional balance, a function that has made it a clinically recognized standard for the SSRI class.


Composition and Physical Form of Zac

The active component, Fluoxetine Hydrochloride, is a synthetic compound, meaning it is chemically manufactured. Zac is supplied as a single active ingredient product, making the therapeutic outcome attributable entirely to the Fluoxetine. For the oral route of administration (swallowing by mouth), the medication is commonly available in oral solid forms, specifically Capsules and Tablets, although an Oral Solution is also manufactured. The availability in multiple oral forms provides flexibility in administration. The active compound is combined with various inactive components, known as Pharmaceutical Excipients, to create the final stable and administrable dosage form.

Regulatory References

  1. NIH MedlinePlus

What side effects are possible with Zac?

Possible Side Effects and Safety Information

The safety profile of Zac, whose active ingredient is Fluoxetine, is documented in official government regulatory sources, which classify adverse reactions based on their frequency and the physiological system affected. This regulatory framework defines the official risk profile without providing prescriptive advice.


Frequency-Classified Adverse Reactions

Adverse reactions are grouped according to how often they are observed:

  • Very Common (Affecting ge 1 in 10 individuals): Headache, Insomnia, Nausea, Diarrhea, and Fatigue.
  • Common (Affecting ge 1 in 100 individuals): Vomiting, Dry mouth, Dizziness, Somnolence (Drowsiness), Tremor, Anxiety, Nervousness, various forms of Sexual Dysfunction, Hyperhidrosis (sweating), Weight loss, and Rash.

Reactions are also categorized by System-Organ-Class, including Psychiatric, Nervous system, Gastrointestinal, and Skin disorders.


Serious Adverse Reactions and Safety Constraints

Official labeling highlights certain clinically important reactions and restrictions:

  • Serious Adverse Reactions: These include Serotonin Syndrome, which is a potentially life-threatening reaction, QT Prolongation (a cardiac rhythm change), and the risk of Suicidal Thoughts and Behavior, which is documented as being elevated in children, adolescents, and young adults, particularly early in treatment or following dose adjustments.
  • Population-Specific Notes: Lower or less frequent dosing may be required for individuals with Hepatic Impairment due to reduced drug clearance. Older Adults may be more susceptible to events like Hyponatremia (low sodium levels in the blood).
  • Restrictions: Use of Fluoxetine is contraindicated (prohibited) concurrently with MAOIs (Monoamine Oxidase Inhibitors) or within a specified washout period, as well as with certain other medications such as Pimozide and Thioridazine, due to serious safety risks.

Overdose and Emergency Response

An overdose of Fluoxetine (Zac) is documented in regulatory sources as potentially affecting the central nervous system, cardiovascular system, and gastrointestinal system. Documented clinical manifestations of overdose include common signs such as agitation, confusion, tremor, shivering, nausea, and vomiting. More severe presentations noted in official labeling involve somnolence, tachycardia (rapid heart rate), and altered mental status.

Severe and Life-Threatening Outcomes

Official labeling notes the potential for severe and life-threatening complications. These serious outcomes include seizures, coma, and the development of Serotonin Syndrome. Cardiovascular risks are a critical concern, specifically the potential for ventricular arrhythmia like Torsades de Pointes, associated with documented QTc prolongation. Overdoses involving multiple drugs or alcohol have been associated with fatal outcomes. Due to the long elimination half-lives of Fluoxetine, active drug substance can persist in the body for weeks.

When to Seek Immediate Help

In the event of a suspected overdose, regulatory guidance mandates specific emergency actions. Contact a Poison Control Center for advice. Immediate medical attention is required, and emergency services must be called if the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. Management procedures focus on general supportive and symptomatic treatment, including continuous cardiac rhythm monitoring, as there is no specific antidote known.

Therapeutic Uses of Zac

Zac is commonly used across therapeutic domains that involve certain distressing symptoms related to mood, anxiety, and impulse control. This medication is applied in clinical settings where patients experience the functional strain of conditions characterized by periods of heightened symptoms, such as Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, Bulimia Nervosa, and Premenstrual Dysphoric Disorder (PMDD).

“It is used to address core symptoms such as profound sadness, loss of pleasure (anhedonia), and feelings of hopelessness, as well as to ease the intensity of recurrent, intrusive thoughts and anxiety episodes.”

Therapeutic Support and Symptom Management

Zac provides support that helps ease the distressing manifestations of these conditions. It is applied in clinical settings that involve acute or unstable symptom patterns, such as periods of heightened depression or the severe cyclical mood changes associated with PMDD. This may contribute to maintaining emotional stability and functional ability. The medication is relevant for managing symptoms that interfere with daily comfort, including obsessive thoughts, compulsive behaviors, and binge-eating patterns. This provides symptomatic relief that helps patients cope more steadily with these difficult, disruptive episodes.


Quick Fact: Relief for Obsessive, Compulsive, and Panic Symptoms Zac is commonly used to help manage the frequency and intensity of intrusive obsessions, compulsions that interfere with daily functioning, and acute, unexpected panic attacks.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Zac (Fluoxetine) eligibility is strictly defined by official regulatory documents, which delineate populations approved for use, those restricted, and those absolutely prohibited.

Absolute Contraindications

The medicine is contraindicated in patients with a known hypersensitivity to Fluoxetine or any product component. Use is also prohibited for patients concurrently receiving or recently having discontinued a Monoamine Oxidase Inhibitor (MAOI), Pimozide, or Thioridazine.

Age and Condition-Based Restrictions

  • Adults are eligible for all labeled indications. Pediatric use is established only for Major Depressive Disorder (8–18 years) and Obsessive-Compulsive Disorder (7–17 years); use is not established outside of these specific age/indication parameters.
  • Patients with Hepatic Impairment (cirrhosis) or geriatric patients require special consideration for dosage.
  • Use requires caution in populations with a history of seizures or risk factors for QT prolongation.

Reproductive Status

For pregnant women, use is conditional and should occur only if the potential benefit justifies the potential risk. Breastfeeding is not recommended as the drug and its metabolite are present in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Zac (Fluoxetine) has officially documented interaction patterns primarily involving pharmacodynamic effects and metabolic enzyme inhibition, as stated in regulatory documents.


Formal Interaction Restrictions

Classification Interacting Agents
Contraindicated Combinations Monoamine Oxidase Inhibitors (MAOIs), Pimozide, Thioridazine, Linezolid, Intravenous Methylene Blue.
Mandatory Timing Rules A washout period of 5 weeks is required after discontinuing Zac before initiating a psychiatric MAOI or Thioridazine. A 14-day period is required after stopping a psychiatric MAOI before starting Zac.

Pharmacokinetic and Pharmacodynamic Effects

Fluoxetine is documented as a potent inhibitor of the CYP2D6 enzyme, which can significantly increase the plasma concentration of co-administered drugs metabolized by this pathway, including specific antipsychotics and Tricyclic Antidepressants (TCAs). This is classified as a pharmacokinetic interaction.

A separate pharmacodynamic interaction occurs when Zac is combined with other serotonergic agents (such as Triptans, Lithium, and the herbal product St. John's Wort), which increases the official risk of Serotonin Syndrome. Additionally, co-administration with agents that interfere with hemostasis, such as NSAIDs and Warfarin, is officially associated with an increased risk of Abnormal Bleeding.

For specific populations, documentation notes that patients with hepatic impairment (cirrhosis) exhibit a prolonged elimination half-life, which alters the exposure profile and potential for drug accumulation.

Mechanism of Action

Targeting the Serotonin Reuptake Transporter

This mechanism is initiated by the drug's targeted interaction with the Serotonin Transporter (SERT), a specialized protein responsible for the reuptake of the neurotransmitter serotonin (5-HT) from the synaptic cleft. By functioning as a selective inhibitor of this reuptake process, Fluoxetine immediately increases the extracellular concentration of 5-HT available for postsynaptic receptor interaction.

Neural Circuit Adaptation and Long-Term Signal Enhancement

The resulting sustained elevation of synaptic 5-HT triggers a slower, necessary process of neuroadaptation within the central nervous system. This cascade involves the gradual desensitization of presynaptic regulatory autoreceptors and the promotion of neuroplasticity through factors like Brain-Derived Neurotrophic Factor (BDNF). This physiological re-calibration facilitates the structural and functional re-organization of neural pathways, influencing the long-term signaling efficiency within central regulatory circuits.

Dosage and Administration Information

How to Use Zac (Azithromycin) — Official Administration Guidelines

This information details the instructions for using Azithromycin (Zac).


Administration Requirements

Feature Official Labeled Instruction
Route(s) of Administration Oral (tablets, suspension) and Intravenous (IV) Infusion.
Frequency Pattern Typically once daily (qDay) for multi-day regimens, or a single dose for some infections.
Standard Course Examples A 5-day course (500 mg Day 1, then 250 mg Days 2-5) or a 3-day course (500 mg daily for 3 days).

Practical Administration Details

Meal Timing: Tablets and standard oral suspension may be taken with or without food. However, the extended-release oral suspension must be taken on an empty stomach (e.g., at least 1 hour before or 2 hours after a meal).

Preparation: The powder for oral suspension must be reconstituted with the specified amount of water and shaken well prior to use. The IV form requires reconstitution and subsequent dilution into a final volume for slow infusion.

Special Conditions:

  • IV Infusion Rate: Must be administered slowly over a period of at least 60 minutes.
  • Pediatric Dosing: Dosing for children is calculated based on body weight (mg/kg).
  • Missed Dose: Take the missed dose as soon as remembered. Subsequent doses should be taken at the next regular time; do not take two doses at once.

It is mandatory to complete the full prescribed course of therapy, even if symptoms improve.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Core Efficacy Research

Current research on the studied compound, which is a treatment derived from the Andrographis paniculata plant, has explored its potential applications, primarily focusing on respiratory infections.

  • Common Cold and Upper Respiratory Tract Infections (URTIs): Research has explored whether the compound is associated with a reduction in the duration and severity of the common cold. Studies have examined whether it influences immune function in healthy adults. A 2018 meta-analysis reviewed 33 randomized, controlled trials. These trials examined whether the compound could modify symptoms and duration across different populations. Results from these studies suggest a possible influence on symptom modification, although the overall evidence remains limited due to the varied quality of the included studies. Findings are being explored regarding the timing of effect onset, and data regarding tolerability and safety for short-term use have been documented in the research.

  • Viral Activity: Research has investigated the compound's interaction with viral replication processes and certain immune system components. Several in-vitro (laboratory) and animal model studies have explored this area. One key preclinical study examined the compound's influence on influenza virus, with findings including data on a measured reduction in viral load.


Pharmacokinetic and Safety Profile

The focus of pharmacokinetic research has been to understand how the compound is processed by the body.

  • Absorption and Metabolism: Studies have explored whether the combination influences the bioavailability of the active component. The findings indicate a difference in measured concentration, where the combination was associated with a higher measured amount in the bloodstream compared to the single compound alone.
  • Use in Specific Populations: Studies in adults were designed to assess the compound when initiated at the first report of symptoms. Further research has examined the compound in children over the age of two. Individuals with severe allergies were excluded from clinical trials. Information on use during pregnancy or while breastfeeding remains limited or unavailable from published research.

Frequently Asked Questions (FAQ)

Common questions about Zac (FAQ)


Q: How quickly does Zac typically begin to show its effects?

A: Studies and official information indicate that earlier changes may occur, but the full therapeutic effect of Zac may take four weeks or longer to become noticeable. This timeline is associated with the process of neuroadaptation in the central nervous system, where steady-state plasma levels are typically achieved after several weeks of consistent use.

Q: Does Zac interact with common over-the-counter pain relievers like ibuprofen?

A: Yes, official regulatory documents state that co-administration with certain over-the-counter pain relievers, specifically Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like ibuprofen, increases the official risk of bleeding events.

Q: What kind of warnings are included on the official regulatory label for Zac?

A: The official labeling includes a prominent Boxed Warning concerning the increased risk of suicidal thoughts and behavior. This risk is particularly noted in children, adolescents, and young adults, especially when they first begin treatment or when the dosage is changed.

Q: Are there any specific foods or drinks that should be avoided while using Zac?

A: Official guidance recommends that alcohol use be avoided as it may worsen some side effects of the medication. While standard tablets and liquid may be taken with or without food, one specific formulation, the extended-release suspension, is required to be taken on an empty stomach.

Q: Does Zac have known interactions with common herbal supplements?

A: Yes, regulatory documentation states that the co-administration of Zac with the herbal product St. John's Wort increases the official risk of Serotonin Syndrome, a serious condition caused by excessive serotonin levels in the body.

Q: Can Zac be used by people who have a history of liver or kidney problems?

A: Official information advises caution for individuals with severe kidney impairment. For those with hepatic impairment (liver damage), a lower or less frequent dose may be necessary because the drug's clearance from the body can be slowed.

Q: What clinical research evidence supports the approved uses of Zac?

A: The approved uses, such as for Major Depressive Disorder and Obsessive-Compulsive Disorder, are supported by evidence from controlled clinical trials. These studies were submitted to and reviewed by regulatory agencies to establish the drug's efficacy and safety profile for its indicated conditions.

Q: Is Zac a medicine that requires a 'Black Box Warning' (Boxed Warning)?

A: Yes, the product carries a Boxed Warning, which is the term for the most serious warning required by the FDA. This warning addresses the increased risk of suicidal thinking and behavior in younger people, particularly when treatment begins.

Q: How long does the active substance of Zac remain detectable in the body?

A: The drug and its active breakdown product (metabolite) have relatively long half-lives. The elimination half-life of the active drug is typically 4 to 6 days, while the metabolite can remain in the body for 4 to 16 days after chronic use.

Q: What are the descriptive signs of a severe or rare adverse reaction to Zac?

A: A potentially severe reaction is Serotonin Syndrome, which can involve symptoms like agitation, confusion, hallucinations, fever, sweating, a fast heart rate, muscle stiffness, and loss of coordination.

Q: Is Zac a treatment or a cure for the condition it addresses?

A: Official documentation indicates that Zac is intended for the acute and maintenance treatment of its approved conditions, meaning it is used to manage symptoms and prevent relapse. It is not described as a cure.

Q: What is the usual duration before peak effect of Zac is seen?

A: The peak concentration of the drug in the bloodstream is typically observed 6 to 8 hours after taking a single oral dose. This is the time when the drug level is highest in the body.

Q: How often do people generally need follow-up appointments when using Zac?

A: Regulatory guidance emphasizes that close monitoring by a healthcare provider is required, especially when first starting treatment or when the dose is changed. This monitoring is required to check for worsening symptoms and the emergence of suicidal thoughts.

Q: What general expectations should I have about the duration of treatment with Zac?

A: Official information indicates the drug is used for both acute (short-term) and maintenance (long-term) treatment. Therefore, the length of time needed can be prolonged, with maintenance treatment sometimes lasting indefinitely.

Q: Is Zac considered an addictive or habit-forming medicine?

A: Zac is not classified as a controlled substance and is not considered addictive. However, the drug can cause physical dependence, and abruptly stopping it may lead to symptoms of discontinuation syndrome.

Q: Can people with high blood pressure safely use Zac?

A: The official label does not list pre-existing high blood pressure as a direct common risk. However, it is noted that high blood pressure can be a symptom of the serious, rare reaction Serotonin Syndrome, and official documentation indicates caution is warranted for cardiac conditions.

Q: Is Zac typically prescribed as a short-term or long-term medicine?

A: The drug is indicated for both the acute phase (short-term) and the maintenance phase (long-term) of treatment for its approved conditions. The required duration depends on the specific condition being managed.

Q: What type of monitoring (blood tests, etc.) is usually associated with Zac use?

A: Monitoring of serum levels for the drug and its active metabolite may be used to help evaluate potential toxicity and to check for patient adherence. This practice is known as Therapeutic Drug Monitoring.

Q: How often do people need to adjust their Zac usage?

A: According to official guidelines, dosage adjustments are typically considered after several weeks if the initial dosage does not lead to a sufficient clinical response. Adjustments are based on the individual's response and tolerability.

Q: Does Zac interact with birth control pills?

A: Regulatory analyses and clinical studies generally suggest that Zac does not compromise the effectiveness of most common hormonal birth control methods. However, because Zac is a potent enzyme inhibitor, official documentation warrants caution with any co-administered medications.

Q: Are there any known issues with taking Zac with dairy products?

A: Food does not appear to affect the overall absorption of the drug. However, due to its chemical makeup, some tablet forms of the drug may contain excipients (inactive ingredients) that can react with lactose or other dairy components over time.

Q: Does Zac cause blurred vision or changes in eyesight?

A: Blurred vision is listed as a possible adverse reaction. More seriously, the drug can cause pupillary dilation, which may trigger an acute angle-closure glaucoma attack in predisposed patients.

How should Zac be stored and disposed of?

How to Store and Dispose of Zac?

The official storage and disposal guidelines for Zac (Fluoxetine) are structured to maintain product integrity and ensure safety, as specified by regulatory documents.

Storage Requirement Official Mandate
Temperature and Environment Must be stored at room temperature, typically below 25 C (77 F), protected from excess heat, light, and moisture.
Container and Integrity Keep the medication in its original container with the lid tightly closed. The oral solution may need to be discarded 60 days after first opening.
Child Safety It is mandatory to keep the product out of the sight and reach of children by using a safety-locked cap.
Disposal Unused or expired medication should be taken to an official drug take-back program. Household disposal requires mixing the product with an unpalatable substance before sealing it and discarding it in the trash; the product must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zac found in:

A-Z Index: